Assembly Biosciences reports positive interim Phase 1a results for ABI-5366 in recurrent genital herpes

ASSEMBLY BIOSCIENCES, INC.

ABI-5366 was well-tolerated with favorable safety profile and exposure up to 70 days in healthy participants.
Half-life of approximately 20 days supports both once-weekly and once-monthly oral dosing schedules.
Screening for Phase 1b in participants with recurrent genital herpes is now underway.
Interim Phase 1b results are expected in the first half of 2025.
Single doses of ABI-5366 surpassed target plasma concentrations for antiviral efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.